Exceptional circumstances is granted when complete data cannot be obtained, and it carries annual reassessment and specific post-authorisation obligations. Every member-state HTA body will read that as a conditional evidence position, so first approved in Europe and reimbursed in Europe are separate milestones here, and the second will arrive country by country.

• The label is an early-disease window defined by MRI. Gadolinium-negative lesions precede active inflammation. Eligible boys come from MRI surveillance of those already known to carry ALD, which makes newborn screening coverage the real market size.
• Transplant and gene therapy are the comparators. An oral drug competes on risk and logistics with haematopoietic stem cell transplant, not on replacing it, and is most likely to bridge or to serve boys ineligible for either.
• CALYX 2 in adults is the next value step. Minoryx is generating data in adult men with enhancing lesions to support a US filing and an EU label expansion into a larger, sicker population.

This is the first positive placebo-controlled trial in a genetic ALS subtype on a clinical composite. Tofersen reached approval on a neurofilament surrogate after missing its functional primary; ulefnersen has the clinical win, from the same Ionis antisense chemistry, which strengthens the case for every allele-targeted ALS programme behind it.

• Early access came first and that is deliberate. A programme opened the day before topline means Otsuka had supply and eligibility ready, so patients reach drug before any filing is reviewed.
• Paediatric onset raises the urgency and the burden. Juvenile FUS-ALS can progress to respiratory failure within one to two years, and repeated intrathecal dosing in children needs specialist centres.
• Effect size is still undisclosed. Ask for the win ratio and the neurofilament change at congress, because they will decide the regulatory route.

A competing RPGR gene therapy missed its pivotal primary before this readout, so Beacon’s result resets the category rather than joining it. The untreated control, rather than a sham procedure, is the design point regulators will probe, and a zero control responder rate is the best answer Beacon could have.

• The low dose won on 10-letter gains. 58.6% against 48.3% for the high dose is non-monotonic, and dose selection for the label is not settled.
• Syncona now has a monetisable asset. It held its 38.4% stake at £183.4 million at 30 June and names financing, an IPO or a sale as next steps.
• Launch will run through retinal surgeons. Subretinal delivery needs a vitrectomy, so uptake follows specialist centre capacity rather than prescriber demand.

Therapeutic equivalence is the access finding, because it allows substitution. For the first time a radioligand enters the formulary mechanics that govern generic small molecules, although substitution will run through nuclear medicine purchasing contracts rather than at a pharmacy counter.

• Supply decides the first year, not price. Lutetium-177 doses are made to order with short half-lives, and Lantheus names reliable supply as its launch focus. A generic that misses a treatment date is not a substitute.
• Read it against the week’s biggest deal. Telix paid $1.65 billion for ITM, whose Phase III ITM-11 is a lutetium-based SSTR therapy in GEP-NETs, with up to $450 million of milestones tied to ITM-11 sales. It will launch into a market where the reference product now has two challengers.
• Lantheus is itself being acquired. Curium agreed to buy Lantheus in the $8.0 billion deal covered in NeuroPulse Week 33, so Bravnetsa joins a combined isotope supplier.

Seven children, open label and no control, in a field where the benchmarks are placebo-controlled. BridgeBio’s oral infigratinib added 1.74 cm/year over placebo in Phase 3 PROPEL 3, and vosoritide’s pivotal study added about 1.57 cm/year. A within-patient change of 2.4 cm/year is not comparable to either, because growth velocity in achondroplasia falls with age and uncontrolled baselines flatter the result.

• Selectivity is the real differentiation. Hyperphosphatemia and corneal effects come from inhibiting other FGFR family members. Avoiding them at efficacious doses would be a safety argument against less selective oral competitors.
• Formulation is a competitive feature here. Abbisko built mini-tablets under 3 mm for young children, and in a daily chronic paediatric therapy formulation drives adherence.
• The realistic position is fast follower. Infigratinib has Phase 3 data; lavengratinib has 27 weeks in seven patients. The higher-dose cohorts decide whether it can be a better follower.

Moving from refractory to newly diagnosed patients multiplies the eligible population, because refractory patients are the minority who fail standard therapy. The access question is whether payers accept a symptom score as the primary for a drug whose value has always been argued on culture conversion.

• The confirmatory obligation is arriving late. Accelerated approval in 2018 and a full approval decision in 2027 is nearly nine years on a surrogate, the timeline current FDA policy on accelerated approval is designed to shorten.
• The missing numbers are the ones that set formulary position. No conversion rates, times to conversion or arm-level adverse event rates have been published yet.
• Japan is next. Insmed will discuss ENCORE with the PMDA in Q4 2026, and a Japan-specific endpoint was built into the trial.

Two paediatric applications split by body weight and sequenced months apart tell you the January complete response concerned manufacturing analytics rather than clinical evidence. The 24 October date is the one that matters: if it clears, the lower-dose file becomes a formality on the same dataset.

• Children are the patients APDS reaches first. The disease presents in childhood, so an adolescent and adult label strands the group where early treatment changes the course of lymphoproliferation and infection.
• This extends the Week 33 launch story. OrphanPulse covered the Japanese launch for ages 4 and over in August; the US paediatric label is the larger commercial prize and still trails Japan.
• Batch-testing complete responses are fixable and recurring. They cost less to resolve than efficacy questions, but they show CMC scrutiny on small-volume rare disease products is not easing.

Designation stacking usually finances early assets. Here it finances a label for a practice that already exists, and the seven years of US orphan exclusivity would protect Qivigy’s label, not IVIG as a class.

• The trial is small and the endpoint undisclosed. Fluctuating stiffness makes SPS a hard indication to measure in 24 weeks.
• A CAR-T competitor is ahead. Kyverna’s CD19 CAR-T ran a 25-patient registrational study on the timed 25-foot walk.
• Plasma supply is the operational constraint. Every new IVIG indication draws on the same donor base as immunodeficiency patients.

Pretzel reports preclinical activity across the four most common POLG mutations, covering about 70% of patients. A single molecule that works across variants is the commercial case in a disease otherwise approached one mutation at a time.

• No patient data exist yet. POLARIS is doing dose-finding and proof of concept together.
• Mitochondrial DNA copy number is not an accepted surrogate. The primary endpoint choice will decide whether POLARIS can support registration.
• Log the designation as positioning. Fast Track confirms unmet need and buys meetings, not evidence.

An option on a whole company is the cheapest way to hold two paediatric kidney programmes without committing money from a Series B that has not closed. The option and the financing are effectively one transaction, and whichever lands first will decide the other.

• Childhood nephrotic syndrome is a steroid problem. Most children respond to corticosteroids; the unmet need is the relapsing and steroid-dependent group exposed to repeated courses. Ask which subgroup LOKID enrols.
• Lobeglitazone is a repurposed diabetes drug. It is a thiazolidinedione approved in South Korea, and repurposing a PPAR gamma agonist for podocyte protection is plausible and cheap to develop.
• Cystinuria is the stray. An IND-stage kidney stone disease sits oddly beside two Phase II nephrotic programmes and is the likeliest asset to be deprioritised.